• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

    1/24/24 2:33:59 PM ET
    $BVXV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BVXV alert in real time by email
    SC 13G/A 1 sc13a2.htm AMENDMENT NO. 2 TO SCHEDULE 13G


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Amendment No. 2 to
    SCHEDULE 13G



    INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    SCINAI IMMUNOTHERAPEUTCS LTD.
    (formerly BiondVax Pharmaceuticals Ltd.)
    (Name of Issuer)




    Ordinary ADS Shares
    (Title of Class of Securities)



    09073Q204
    (CUSIP Number)


    December 31, 2023
    (Date of Event Which Requires Filing of This Statement)


    Check the Appropriate box to designate the rule pursuant to which this schedule is filed:


            Rule 13d-1(b)
    X  Rule 13d-1(c)
          Rule 13d-1(d)




    1
    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
     
     
    DANIEL E. STONE
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a)
    (b)
     
         
    3
    SEC USE ONLY
     
         
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
     
    5
    SOLE VOTING POWER
    NUMBER OF
     
    624,000
    SHARES
    6
    SHARED VOTING POWER
    BENEFICIALLY
     
    0
    OWNED BY
    7
    SOLE DISPOSITIVE POWER
    EACH
     
    624,000
    REPORTING
    8
    SHARED DISPOSITIVE POWER
    PERSON WITH
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    624,000
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* q
     
         
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    12.96%*
    *Based on 4,814,425 issued and outstanding shares of the Issuer as of January 15, 2024.
    12
    TYPE OF REPORTING PERSON*
     
    IN
    *SEE INSTRUCTIONS BEFORE FILLING OUT!


    Item 1 (a). Name of Issuer:

    Scinai Immunotherapeutics Ltd., formerly BiondVax Pharmaceuticals Ltd. (the “Issuer”)

    Item 1 (b). Address of Issuer’s Principal Executive Offices:

    Jerusalem Biopark, 2nd Floor
    Hadassah Ein Kerem Campus
    Jerusalem L3 00000

    Item 2 (a). Name of Person Filing:

    Daniel E. Stone

    Item 2 (b). Address of Principal Business Office or, if None, Residence:

    1200 Brickell Avenue, #1470
    Miami, FL 33131

    Item 2 (c). Citizenship:

    United States

    Item 2 (d). Title of Class of Securities:

    Ordinary ADS Shares

    Item 2 (e). CUSIP Number:

    09073Q204

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    (a)
    Broker or dealer registered under Section 15 of the Act;


    (b)
    Bank as defined in Section 3(a)(6) of the Act;


    (c)
    Insurance Company as defined in Section 3(a)(19) of the Act;


    (d)
    Investment Company registered under Section 8 of the Investment Company Act;


    (e)
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);


    (f)
    Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);


    (g)
    Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);


    (h)
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

    (i)
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:


    (j)
    Group, in accordance with Rule 13d-1(b)(1)(ii)(j).


    X
    If this statement is filed pursuant to Rule 13d-1(c), check this box.

    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.


    (a)
    Amount beneficially owned:

    624,000


    (b)
    Percent of class:

    12.96%


    (b)
    Number of shares as to which such person has:

    (i)
    Sold power to vote or to direct the vote:  624,000

    (ii)  Shared power to vote or to direct the vote:  0

    (iii)  Sole power to dispose or to direct the disposition of:  624,000

    (iv)  Shared power to dispose or to direct the disposition of:  0


    Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    N/A

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    N/A

    Item 8.
    Identification and Classification of Members of the Group.

    N/A

    Item 9.
    Notice of Dissolution of Group.

    N/A


    Item 10. Certification.


    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



     
    January 24, 2024
     
    (Date)
       
       
     
    /s/ Daniel E. Stone
    Daniel E. Stone
     
       
    Get the next $BVXV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVXV

    DatePrice TargetRatingAnalyst
    1/26/2022$7.00Buy
    Aegis Capital
    More analyst ratings

    $BVXV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on BiondVax Pharmaceuticals with a new price target

      Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      1/26/22 10:21:55 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BVXV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 3: New insider Margolin Yael claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:16:22 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Laster Morris C claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:10:29 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Lowell George claimed ownership of 421,680 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:04:49 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by BiondVax Pharmaceuticals Ltd.

      SC 13G - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      2/14/24 3:53:32 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/24/24 2:33:59 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BiondVax Pharmaceuticals Ltd. (Amendment)

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      1/2/24 4:54:14 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

      JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. ("Scinai"). In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices. The new corporate name, which was approved by the Israeli authorities on August 31, is the Company's latest step to better reflect its fresh start and new direction. Scinai and its new symbol, "SCNI", will debut on Nasdaq tomorro

      9/6/23 6:00:00 AM ET
      $APGE
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Reports Second Quarter Financial Results and Provides Business Update

      JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended June 30, 2023, amounted to $1.45 million compared with $1.97 million for the three months ended June 30, 2022.Marketing, general and administrative expenses for the three months ended June 30, 2

      8/11/23 9:00:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

      JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previously disclosed, BiondVax received a deficiency letter dated May 1, 2023, from Nasdaq notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for con

      8/1/23 4:01:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Leadership Updates

    Live Leadership Updates

    See more
    • BiondVax Announces Third Quarter 2020 Financial Results & Business Update

      JERUSALEM, Jan. 28, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced its third quarter financial results for the quarter ended September 30, 2020. Third Quarter 2020 Financial Summary Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.441 (NIS/$US) as at September 30, 2020. Total operating income for the third quarter was NIS 55.6 million (approximately $16.1 million) compared with a total operating loss of NI

      1/28/21 3:23:00 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiondVax Announces Appointment of Amir Reichman as New CEO

      JERUSALEM, Jan. 21, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on development and manufacturing of products for the prevention and treatment of infectious diseases, today announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, BiondVax's founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK), a global pharmaceutical company. Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as Senior Advisor to the Company. Continue Reading BiondVa

      1/21/21 7:15:00 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    SEC Filings

    See more
    • SEC Form EFFECT filed by BiondVax Pharmaceuticals Ltd.

      EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      2/14/24 12:15:33 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form F-3 filed by BiondVax Pharmaceuticals Ltd.

      F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/30/24 4:19:12 PM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.

      6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      1/18/24 11:50:50 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care